The Human Genome consists of around 3 billion nucleotides of DNA. Out of which only 1.5% of those nucleotides get translated into proteins. The exome comprises of all the genome’s exons, which are the coding regions of the genes. Exons are termed as “expressed sequences” because these regions get translated while the introns can be termed as “intervening sequences” as they are not expressed or translated into proteins.
Clinical exome sequencing is a comprehensive DNA test where all the clinically relevant genes are screened using Next-generation sequencing (NGS) technology. Most of the diseases related to genes are caused by mutations in the exome. Coding regions of the DNA are called the exome, which carries out every metabolic function in the human body.
Clinical Exome sequencing is a cost-effective approach when whole-genome sequencing is not necessary or is not required. Sequencing only the coding regions of the genome help the researchers to focus on the genes that are most likely to affect the specific phenotype.
Advantages of Clinical Exome Sequencing
Identifies variants/mutants across a broad range of clinical applications
Achieves comprehensive coverage of coding regions
Provides a cost-effective alternative to whole-genome sequencing
Produces a smaller, more manageable data set for faster, easier data analysis compared to whole-genome approaches
Who
should go for Clinical Exome Sequencing?
Clinical Exome Sequencing is performed during any age of life and is generally performed due to the following reasons:
suspected to have
any genetic condition
have a complex
medical history that may have affected many organs and/or body systems
Inconclusive
previous genetic testing
for prenatal
analysis
Performed for a
range of clinical presentations that require a broad search for variants across
the spectrum.
Over the last few years, advances in next-generation sequencing
technologies have decreased the cost of sequencing, improved accuracy, and also
has improved the turnaround time of generating the data.
Genes2Me offers Clinical Exome Sequencing test for known inherited disorders which covers all exons for ~8.5K genes associated with various diseases. Clinical Exome Sequencing covers all clinically important regions including disease specific hotspot regions at a sequencing depth of >100x.
Published by Genes2Me
Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide.
With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards.
At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes.
In genomics, Genes2Me offers one of the industry’s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease.
Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics—delivering integrated solutions that advance precision medicine and improve lives worldwide.
View all posts by Genes2Me
